Milestone Pharmaceuticals Inc.

NasdaqGS MIST

Milestone Pharmaceuticals Inc. EBITDA Margin for the year ending December 31, 2023: -5,684.50%

Milestone Pharmaceuticals Inc. EBITDA Margin is -5,684.50% for the year ending December 31, 2023, a -386.99% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Milestone Pharmaceuticals Inc. EBITDA Margin for the year ending December 31, 2022 was -1,167.28%, a -307.38% change year over year.
Milestone Pharmaceuticals Inc. EBITDA Margin for the year ending December 31, 2021 was -286.53%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: MIST

Milestone Pharmaceuticals Inc.

CEO	Mr. Joseph G. Oliveto M.B.A.
IPO Date	May 9, 2019
Location	Canada
Headquarters	1111 Dr. Frederik-Philips Boulevard
Employees	47
Sector	Healthcare
Industries Clinical Trials Biotechnology Drugstores & Retail Pharmacies Pharmaceuticals

Description

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Key trends

Past 5 years